Back to Knowledge Center
General Medicine ICD-10: M72.0

Dupuytren Contracture

A progressive thickening of the fascia in the palm, pulling one or more fingers (usually ring or pinky) into a permanently bent position.

Source: WHO / CDC / NIH Evidence Guidelines
Updated: Aug 08, 2026
3,905 Views
Red Flag Warning & Emergency Situations

Emergency Management: Ischemia of the finger after surgical correction due to stretching of chronically contracted, shortened digital arteries; requires immediate surgical release or vessel repair.

Core Definition:

Dupuytren contracture is a benign, slowly progressive fibroproliferative disorder of the palmar fascia. It results in the thickening and shortening of the fascial bands, leading to the formation of palpable nodules and cords that ultimately cause a permanent, irreducible flexion contracture of one or more fingers.

Detailed Overview

The disease primarily affects the ring and small fingers. While the exact etiology is unknown, it involves pathological collagen deposition and myofibroblast proliferation. The condition is usually painless but severely limits hand function, making it difficult to perform tasks like washing one's face, putting hands in pockets, or wearing gloves. Treatment is indicated when functional impairment occurs, ranging from enzymatic injections to complex fasciectomies.

Epidemiology & Demographics

Highly prevalent in people of Northern European (Scandinavian/Celtic) descent ('Viking disease'). Affects men predominantly (M:F ratio 3:1 to 10:1). Onset is typically in the 5th to 7th decades of life.

Etiological Mechanism

Idiopathic and genetically linked. Autosomal dominant inheritance with variable penetrance. It involves mutations in the Wnt signaling pathway regulating fibroblast proliferation.

Primary Causes

Genetic predisposition combined with epigenetic triggers. Not directly caused by repetitive manual labor, though trauma can sometimes precipitate onset in susceptible individuals.

The pathogenesis progresses through three stages: proliferative, involutional, and residual. Normal type I collagen in the palmar fascia is progressively replaced by dense type III collagen. Myofibroblasts proliferate and contract, transforming normal fascial bands into rigid cords. These cords cross the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints, forcing them into flexion. The overlying skin is often drawn in, causing pitting.

Diagnostic Criteria & Guidelines

Clinical diagnosis based on the presence of palmar nodules and cords with digital flexion contractures. A positive 'Hueston Tabletop Test' (patient is unable to place the hand completely flat on a hard surface) indicates readiness for intervention.

First-Line Treatment:

Collagenase Clostridium Histolyticum (Xiaflex) injection: 0.58 mg injected directly into the palpable cord, followed 24-48 hours later by a manual finger extension procedure under local anesthesia to physically rupture the enzymatically weakened cord. Alternatively, Percutaneous Needle Fasciotomy (PNF), utilizing a needle bevel to slice the cord under local anesthesia.

Second-Line & Adjunctive Therapy

Open Surgical Fasciectomy. Regional or limited palmar fasciectomy involves surgical excision of the diseased fascial cords. Indicated for severe contractures (especially involving the PIP joint, which is harder to treat with injections) or rapid recurrences.

Surgical & Procedural Management

Limited fasciectomy requires careful dissection of the digital neurovascular bundles which are often displaced and entwined by the spiral cords of Dupuytren's tissue. Skin grafting may be required if skin is severely contracted.

Patient Counseling & Advice

Warn the patient that there is no 'cure'. Treatments straighten the finger, but the disease is genetic and recurrence rates are high (up to 50% at 5 years depending on the procedure). Hand therapy is critical post-intervention.

Follow-Up & Monitoring Schedule

Close follow-up with a hand therapist post-procedure to monitor range of motion and splint fit. Surgical site checks at 2 and 6 weeks.

Preventive Strategies

No known preventive measures can stop the onset in genetically predisposed individuals.

Good functional outcomes post-treatment, but disease is progressive. Aggressive diathesis (early onset, bilateral, positive family history, ectopic disease like Ledderhose disease of feet) portends a high recurrence rate.

Authoritative Sources & Evidence References
World Health Organization (WHO) & CDC Guidelines: Information compiled from current international clinical practice guidelines.

System Notice

Confirm Action